The firm's net loss in Q1 was up about 60 percent year over year, but it reported plans to share validation data for its lung cancer test next month.
The company plans to use proceeds to advance its lead AR-V7 test with Genomic Health, accelerate other assays in its pipeline, and enhance its technology.
The two studies came out of the UK's Tracking Cancer Evolution through Therapy (TRACERx) trial.
At the AACR annual meeting earlier this month, attendees discussed challenges in demonstrating analytical and clinical validity appropriately for liquid biopsy tests.
At the AACR annual meeting last week researchers presented new data on a range of technologies, discussed novel platforms, compared existing tools, and explored new clinical uses.
Buzzfeed News reports that while companies are hoping to develop liquid biopsy tests to detect early-stage cancer, more data is needed.
Groups from Austria, Spain, Germany, and the US demonstrated that the GeneReader can reliably detect cancer mutations in tissue and liquid biopsy samples.
Presenters highlighted early work that supports the push for a national, systematic effort to elucidate progression from precancerous states to clinical malignancy.
Johns Hopkins University researchers have developed a method called targeted error correction sequencing, or TEC-Seq, to increase liquid biopsy sensitivity.
Eleven laboratories that are part of Thermo's OncoNetwork Consortium tested the Oncomine Lung cfDNA assay on reference samples.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.